相关参考文献
注意:仅列出部分参考文献,下载原文获取全部文献信息。Prognostic role of cell-free DNA biomarkers in pancreatic adenocarcinoma: A systematic review and meta-analysis
Stefania Bunduc et al.
CRITICAL REVIEWS IN ONCOLOGY HEMATOLOGY (2022)
Early assessment of circulating tumor DNA after curative-intent resection predicts tumor recurrence in early-stage and locally advanced non-small-cell lung cancer
Silvia Waldeck et al.
MOLECULAR ONCOLOGY (2022)
Longitudinal analysis of cell-free mutated KRAS and CA 19-9 predicts survival following curative resection of pancreatic cancer
Saskia Hussung et al.
BMC CANCER (2021)
A systematic review and meta-analysis of the association between circulating tumor DNA (ctDNA) and prognosis in pancreatic cancer
Deniz Can Guven et al.
CRITICAL REVIEWS IN ONCOLOGY HEMATOLOGY (2021)
Global cancer statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries
Hyuna Sung et al.
CA-A CANCER JOURNAL FOR CLINICIANS (2021)
Circulating Tumor DNA Detection by Digital-Droplet PCR in Pancreatic Ductal Adenocarcinoma: A Systematic Review
Marisol Huerta et al.
CANCERS (2021)
Extracellular vesicles are the primary source of blood-borne tumour-derived mutant KRAS DNA early in pancreatic cancer
Daniel W. Hagey et al.
JOURNAL OF EXTRACELLULAR VESICLES (2021)
Circulating tumor DNA as a biomarker for monitoring early treatment responses of patients with advanced lung adenocarcinoma receiving immune checkpoint inhibitors
Paul van der Leest et al.
MOLECULAR ONCOLOGY (2021)
Evaluation of circulating cell-free KRAS mutational status as a molecular monitoring tool in patients with pancreatic cancer
Konstantin Schlick et al.
PANCREATOLOGY (2021)
Clinical Utility of Liquid Biopsy-Based Actionable Mutations Detected via ddPCR
Irina Palacin-Aliana et al.
BIOMEDICINES (2021)
Preoperative detection of KRAS G12D mutation in ctDNA is a powerful predictor for early recurrence of resectable PDAC patients
Shiwei Guo et al.
BRITISH JOURNAL OF CANCER (2020)
Circulating Tumor DNA as a Potential Marker to Detect Minimal Residual Disease and Predict Recurrence in Pancreatic Cancer
Jiahong Jiang et al.
FRONTIERS IN ONCOLOGY (2020)
Detection of Circulating Tumor DNA in Patients with Pancreatic Cancer Using Digital Next-Generation Sequencing
Anne Macgregor-Das et al.
JOURNAL OF MOLECULAR DIAGNOSTICS (2020)
Application of liquid biopsy for surgical management of pancreatic cancer
Minako Nagai et al.
ANNALS OF GASTROENTEROLOGICAL SURGERY (2020)
Early Detection of Pancreatic Cancer: Opportunities and Challenges
Aatur D. Singhi et al.
GASTROENTEROLOGY (2019)
Circulating Tumor DNA as a Clinical Test in Resected Pancreatic Cancer
Vincent P. Groot et al.
CLINICAL CANCER RESEARCH (2019)
Circulating tumor DNA as a potential marker of adjuvant chemotherapy benefit following surgery for localized pancreatic cancer
B. Lee et al.
ANNALS OF ONCOLOGY (2019)
International consensus on definition and criteria of borderline resectable pancreatic ductal adenocarcinoma 2017
Shuji Isaji et al.
PANCREATOLOGY (2018)
Repeated mutKRAS ctDNA measurements represent a novel and promising tool for early response prediction and therapy monitoring in advanced pancreatic cancer
S. Kruger et al.
ANNALS OF ONCOLOGY (2018)
Analysis of ctDNA to predict prognosis and monitor treatment responses in metastatic pancreatic cancer patients
He Cheng et al.
INTERNATIONAL JOURNAL OF CANCER (2017)
Current and Emerging Applications of Droplet Digital PCR in Oncology
Susana Olmedillas-Lopez et al.
MOLECULAR DIAGNOSIS & THERAPY (2017)
Early changes in plasma DNA levels of mutant KRAS as a sensitive marker of response to chemotherapy in pancreatic cancer
Marzia Del Re et al.
SCIENTIFIC REPORTS (2017)
Detection of mutant KRAS and TP53 DNA in circulating exosomes from healthy individuals and patients with pancreatic cancer
Sujuan Yang et al.
CANCER BIOLOGY & THERAPY (2017)
High prevalence of mutant KRAS in circulating exosome-derived DNA from early-stage pancreatic cancer patients
K. Allenson et al.
ANNALS OF ONCOLOGY (2017)
Origins, structures, and functions of circulating DNA in oncology
A. R. Thierry et al.
CANCER AND METASTASIS REVIEWS (2016)
Clinical implications of genomic alterations in the tumour and circulation of pancreatic cancer patients
Mark Sausen et al.
NATURE COMMUNICATIONS (2015)
CA19-9 in Potentially Resectable Pancreatic Cancer: Perspective to Adjust Surgical and Perioperative Therapy
Werner Hartwig et al.
ANNALS OF SURGICAL ONCOLOGY (2013)
Cutoff Finder: A Comprehensive and Straightforward Web Application Enabling Rapid Biomarker Cutoff Optimization
Jan Budczies et al.
PLOS ONE (2012)
COSMIC: mining complete cancer genomes in the Catalogue of Somatic Mutations in Cancer
Simon A. Forbes et al.
NUCLEIC ACIDS RESEARCH (2011)
Predictive and Prognostic Value of CA 19-9 in Resected Pancreatic Adenocarcinoma
Joshua G. Barton et al.
JOURNAL OF GASTROINTESTINAL SURGERY (2009)
Perioperative CA19-9 levels can predict stage and survival in patients with resectable pancreatic adenocarcinoma
Cristina R. Ferrone et al.
JOURNAL OF CLINICAL ONCOLOGY (2006)
Classification of surgical complications - A new proposal with evaluation in a cohort of 6336 patients and results of a survey
D Dindo et al.
ANNALS OF SURGERY (2004)